Literature DB >> 14722621

The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.

Akito Tanoue1, Shuji Ito, Kenji Honda, Sayuri Oshikawa, Yoko Kitagawa, Taka-Aki Koshimizu, Toyoki Mori, Gozoh Tsujimoto.   

Abstract

The neurohypophyseal peptide [Arg(8)]-vasopressin (AVP) exerts major physiological actions through three distinct receptor isoforms designated V1a, V1b, and V2. Among these three subtypes, the vasopressin V1b receptor is specifically expressed in pituitary corticotrophs and mediates the stimulatory effect of vasopressin on ACTH release. To investigate the functional roles of V1b receptor subtypes in vivo, gene targeting was used to create a mouse model lacking the V1b receptor gene (V1bR-/-). Under resting conditions, circulating concentrations of ACTH and corticosterone were lower in V1bR-/- mice compared with WT mice (V1bR+/+). The normal increase in circulating ACTH levels in response to exogenous administration of AVP was impaired in V1bR-/- mice, while corticotropin-releasing hormone-stimulated ACTH release in the V1bR-/- mice was not significantly different from that in the V1bR+/+ mice. AVP-induced ACTH release from primary cultured pituitary cells in V1bR-/- mice was also blunted. Furthermore, the increase in ACTH after a forced swim stress was significantly suppressed in V1bR-/- mice. Our results clearly demonstrate that the V1b receptor plays a crucial role in regulating hypothalamic-pituitary-adrenal axis activity. It does this by maintaining ACTH and corticosterone levels, not only under stress but also under basal conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722621      PMCID: PMC311433          DOI: 10.1172/JCI19656

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.

Authors:  M Thibonnier; P Coles; A Thibonnier; M Shoham
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  Molecular pharmacology and modeling of vasopressin receptors.

Authors:  M Thibonnier; P Coles; A Thibonnier; M Shoham
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

3.  Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin.

Authors:  R H Michell; C J Kirk; M M Billah
Journal:  Biochem Soc Trans       Date:  1979-10       Impact factor: 5.407

4.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

5.  Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin.

Authors:  C Rivier; W Vale
Journal:  Nature       Date:  1983 Sep 22-28       Impact factor: 49.962

6.  Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo.

Authors:  C Rivier; W Vale
Journal:  Endocrinology       Date:  1983-09       Impact factor: 4.736

7.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Authors:  S Jard; R C Gaillard; G Guillon; J Marie; P Schoenenberg; A F Muller; M Manning; W H Sawyer
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

8.  Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin.

Authors:  G E Gillies; E A Linton; P J Lowry
Journal:  Nature       Date:  1982-09-23       Impact factor: 49.962

9.  Corticotropin-releasing factor-immunoreactive neurons of the paraventricular nucleus become vasopressin positive after adrenalectomy.

Authors:  J Z Kiss; E Mezey; L Skirboll
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

10.  Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects.

Authors:  U von Bardeleben; F Holsboer; G K Stalla; O A Müller
Journal:  Life Sci       Date:  1985-10-28       Impact factor: 5.037

View more
  65 in total

1.  The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance.

Authors:  Justin L Grobe; Connie L Grobe; Terry G Beltz; Scott G Westphal; Donald A Morgan; Di Xu; Willem J de Lange; Huiping Li; Koji Sakai; Daniel R Thedens; Lisa A Cassis; Kamal Rahmouni; Allyn L Mark; Alan Kim Johnson; Curt D Sigmund
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

2.  V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity.

Authors:  Taka-aki Koshimizu; Yoshihisa Nasa; Akito Tanoue; Ryo Oikawa; Yuji Kawahara; Yasushi Kiyono; Tetsuya Adachi; Toshiki Tanaka; Tomoyuki Kuwaki; Toyoki Mori; Satoshi Takeo; Hitoshi Okamura; Gozoh Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

4.  Quantifying nonlinear interactions within the hypothalamo-pituitary-adrenal axis in the conscious horse.

Authors:  Daniel M Keenan; Sue Alexander; Clifford Irvine; Johannes D Veldhuis
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

5.  Social dominance in male vasopressin 1b receptor knockout mice.

Authors:  Heather K Caldwell; Obianuju E Dike; Erica L Stevenson; Kathryn Storck; W Scott Young
Journal:  Horm Behav       Date:  2010-03-16       Impact factor: 3.587

Review 6.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

7.  Role of vasopressin V1a receptor in ∆9-tetrahydrocannabinol-induced cataleptic immobilization in mice.

Authors:  Nobuaki Egashira; Emi Koushi; Takayuki Myose; Akito Tanoue; Kenichi Mishima; Ryota Tsuchihashi; Junei Kinjo; Hiroyuki Tanaka; Satoshi Morimoto; Katsunori Iwasaki
Journal:  Psychopharmacology (Berl)       Date:  2017-09-14       Impact factor: 4.530

8.  Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist.

Authors:  J A Roper; M Craighead; A-M O'Carroll; S J Lolait
Journal:  J Neuroendocrinol       Date:  2010-11       Impact factor: 3.627

9.  A complex selection signature at the human AVPR1B gene.

Authors:  Rachele Cagliani; Matteo Fumagalli; Uberto Pozzoli; Stefania Riva; Matteo Cereda; Giacomo P Comi; Linda Pattini; Nereo Bresolin; Manuela Sironi
Journal:  BMC Evol Biol       Date:  2009-06-01       Impact factor: 3.260

10.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.